DNB Asset Management Trims Johnson & Johnson Stake

Asset manager sells nearly 95,000 shares of pharmaceutical giant

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

DNB Asset Management AS, a Norwegian investment firm, reduced its holdings in Johnson & Johnson (NYSE: JNJ) by 7.6% in the third quarter of 2025, selling 94,911 shares. The firm now owns 1,161,215 shares of the pharmaceutical company, which make up approximately 0.8% of its investment portfolio.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a significant presence in pharmaceuticals, medical devices, and consumer products. Changes in ownership by major institutional investors can signal shifts in market sentiment or portfolio rebalancing.

The details

According to a filing with the U.S. Securities and Exchange Commission, DNB Asset Management sold the 94,911 shares of Johnson & Johnson during the third quarter of 2025. The firm's total holdings in JNJ are now valued at $215,312,000, down from $230,812,000 at the end of the prior quarter.

  • DNB Asset Management reported the sale in a 13F filing for the third quarter of 2025.

The players

DNB Asset Management AS

A Norwegian investment management firm that oversees approximately $200 billion in assets.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

The reduction in DNB Asset Management's Johnson & Johnson holdings, while relatively small, could signal broader portfolio adjustments or a shift in sentiment around the pharmaceutical giant. Investors will likely monitor future filings to see if other major institutions make similar moves.